INS and type 2 diabetes mellitus: As a novel insulin secretagogue mechanism, it is important to determine whether GPR142 agonists stimulate insulin secretion only in the presence of high ambient glucose, which is essential for a desired safety profile for the treatment of type 2 diabetes.